JP2014528403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528403A5 JP2014528403A5 JP2014532481A JP2014532481A JP2014528403A5 JP 2014528403 A5 JP2014528403 A5 JP 2014528403A5 JP 2014532481 A JP2014532481 A JP 2014532481A JP 2014532481 A JP2014532481 A JP 2014532481A JP 2014528403 A5 JP2014528403 A5 JP 2014528403A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- pyrazol
- urea
- tert
- naphthalen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- -1 3- (tert-butyl) -1- (p-tolyl) -1H-pyrazol-5-yl Chemical group 0.000 claims 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims 5
- 206010014561 Emphysema Diseases 0.000 claims 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 5
- 206010006451 bronchitis Diseases 0.000 claims 5
- 208000029771 childhood onset asthma Diseases 0.000 claims 5
- 208000007451 chronic bronchitis Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 201000000306 sarcoidosis Diseases 0.000 claims 5
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 4
- 206010012434 Dermatitis allergic Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010033645 Pancreatitis Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 4
- 201000010105 allergic rhinitis Diseases 0.000 claims 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- 208000010247 contact dermatitis Diseases 0.000 claims 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010039083 rhinitis Diseases 0.000 claims 4
- 201000009890 sinusitis Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 210000001503 joint Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- UBHCCGHQPDLGDY-UHFFFAOYSA-N 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-hydroxyphenyl)pyrazol-3-yl]urea Chemical compound C=1C=C(O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1NC1=CC=CC=C1 UBHCCGHQPDLGDY-UHFFFAOYSA-N 0.000 claims 1
- WMEVWPPRBPPTRV-UHFFFAOYSA-N 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 WMEVWPPRBPPTRV-UHFFFAOYSA-N 0.000 claims 1
- DBXJNQABFNNKPN-UHFFFAOYSA-N 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 DBXJNQABFNNKPN-UHFFFAOYSA-N 0.000 claims 1
- YEMXWTXOSTZPEB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC(O)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 YEMXWTXOSTZPEB-UHFFFAOYSA-N 0.000 claims 1
- NSYKHTWNGWUTST-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2,4-dihydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)O)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 NSYKHTWNGWUTST-UHFFFAOYSA-N 0.000 claims 1
- PHWDSIFWTAWWTO-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2,4-dimethoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound COC1=CC(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 PHWDSIFWTAWWTO-UHFFFAOYSA-N 0.000 claims 1
- ONVRBAWIVFIJHQ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2,5-dimethylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=C(C)C=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 ONVRBAWIVFIJHQ-UHFFFAOYSA-N 0.000 claims 1
- FTOGPTPILJXAPZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-chloro-4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)Cl)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 FTOGPTPILJXAPZ-UHFFFAOYSA-N 0.000 claims 1
- KPHLJVDHJFLLFQ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-fluoro-4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)F)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 KPHLJVDHJFLLFQ-UHFFFAOYSA-N 0.000 claims 1
- YSCGLTBNMHIWFZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-fluoroanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=CC=4)F)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 YSCGLTBNMHIWFZ-UHFFFAOYSA-N 0.000 claims 1
- OKZIGNXMBPUUKU-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound COC1=CC=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 OKZIGNXMBPUUKU-UHFFFAOYSA-N 0.000 claims 1
- IHAAICCNNPXTHZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=CC=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 IHAAICCNNPXTHZ-UHFFFAOYSA-N 0.000 claims 1
- AUNDYKNGIPQOPL-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-propan-2-ylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound CC(C)C1=CC=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 AUNDYKNGIPQOPL-UHFFFAOYSA-N 0.000 claims 1
- KNRZDHNOISHOGX-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3,4-dimethoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 KNRZDHNOISHOGX-UHFFFAOYSA-N 0.000 claims 1
- VOHADHHZHANGKB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-chloro-4-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=C(Cl)C(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 VOHADHHZHANGKB-UHFFFAOYSA-N 0.000 claims 1
- PDEVFPKHVTXCFJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-fluoro-4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(F)C(O)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 PDEVFPKHVTXCFJ-UHFFFAOYSA-N 0.000 claims 1
- QJGQXNFWEATZQP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-fluoroanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(F)C=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 QJGQXNFWEATZQP-UHFFFAOYSA-N 0.000 claims 1
- HICTUWNTIGIPDG-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-hydroxy-4-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(O)C(C)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HICTUWNTIGIPDG-UHFFFAOYSA-N 0.000 claims 1
- HFJAHIJCNYORLF-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(O)C=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HFJAHIJCNYORLF-UHFFFAOYSA-N 0.000 claims 1
- DQXDDNKSKQUYFA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound COC1=CC=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 DQXDDNKSKQUYFA-UHFFFAOYSA-N 0.000 claims 1
- CKGGLZNZJRZRTM-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C)C=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 CKGGLZNZJRZRTM-UHFFFAOYSA-N 0.000 claims 1
- HAKVAEKWYIEPSR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-chloro-2-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(Cl)=CC=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HAKVAEKWYIEPSR-UHFFFAOYSA-N 0.000 claims 1
- CTDYPDKXAYTBGR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-ethoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(OCC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 CTDYPDKXAYTBGR-UHFFFAOYSA-N 0.000 claims 1
- VBXDFGPLWMFEQW-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-fluoroanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC(F)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 VBXDFGPLWMFEQW-UHFFFAOYSA-N 0.000 claims 1
- JLWQAVMMXAMIFK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxy-2-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 JLWQAVMMXAMIFK-UHFFFAOYSA-N 0.000 claims 1
- VPQXOTKFLVTQBB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxy-3-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=C(O)C(OC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 VPQXOTKFLVTQBB-UHFFFAOYSA-N 0.000 claims 1
- VFDXVDLISMVQFY-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC(O)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 VFDXVDLISMVQFY-UHFFFAOYSA-N 0.000 claims 1
- AIRVOCDKJXGJQV-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 AIRVOCDKJXGJQV-UHFFFAOYSA-N 0.000 claims 1
- CXRISVPNMXQWAR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 CXRISVPNMXQWAR-UHFFFAOYSA-N 0.000 claims 1
- 208000014085 Chronic respiratory disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- 229960002194 oseltamivir phosphate Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183688.8A EP2578582A1 (en) | 2011-10-03 | 2011-10-03 | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| EP11183688.8 | 2011-10-03 | ||
| PCT/GB2012/052444 WO2013050756A1 (en) | 2011-10-03 | 2012-10-03 | L-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p3i map kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528403A JP2014528403A (ja) | 2014-10-27 |
| JP2014528403A5 true JP2014528403A5 (OSRAM) | 2015-10-08 |
| JP6023204B2 JP6023204B2 (ja) | 2016-11-09 |
Family
ID=47018246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532481A Active JP6023204B2 (ja) | 2011-10-03 | 2012-10-03 | ｐ３ｉＭＡＰキナーゼ阻害剤としてのｌ−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US9475796B2 (OSRAM) |
| EP (2) | EP2578582A1 (OSRAM) |
| JP (1) | JP6023204B2 (OSRAM) |
| WO (1) | WO2013050756A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| EP2531502B1 (en) | 2010-02-01 | 2014-04-02 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PL2763984T3 (pl) | 2011-10-03 | 2016-10-31 | 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP | |
| GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) * | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| WO2014162121A1 (en) | 2013-04-02 | 2014-10-09 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| EP2981535B8 (en) | 2013-04-02 | 2021-03-10 | Oxular Acquisitions Limited | Urea derivatives useful as kinase inhibitors |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| EP3083604A1 (en) | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| JP6586098B2 (ja) | 2014-02-14 | 2019-10-02 | レスピバート・リミテツド | キナーゼ阻害剤としてのピラゾリル尿素 |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| BR112018067552A2 (pt) | 2016-04-06 | 2019-01-08 | Topivert Pharma Ltd | inibidores de cinase |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT991625E (pt) | 1997-06-19 | 2005-10-31 | Bristol Myers Squibb Pharma Co | Inibidores de factor xa com um grupo de especificidade p1 neutro |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| PL341356A1 (en) | 1997-12-22 | 2001-04-09 | Bayer Ag | Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas |
| DE69836563T2 (de) | 1997-12-22 | 2007-05-16 | Bayer Pharmaceuticals Corp., West Haven | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
| WO2001036403A1 (en) | 1999-11-16 | 2001-05-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Urea derivatives as anti-inflammatory agents |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| US6916814B2 (en) | 2001-07-11 | 2005-07-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| WO2003072569A1 (en) * | 2002-02-25 | 2003-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
| US20070078121A1 (en) | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
| GB0500435D0 (en) | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
| PE20070640A1 (es) | 2005-10-28 | 2007-08-10 | Lilly Co Eli | Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38 |
| KR20130087054A (ko) | 2006-04-04 | 2013-08-05 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| AU2007325576B2 (en) | 2006-10-20 | 2013-01-10 | Icos Corporation | Compositions of Chk1 inhibitors |
| KR101713501B1 (ko) | 2008-03-17 | 2017-03-07 | 암비트 바이오사이언시즈 코포레이션 | Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법 |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| EP2370428B1 (en) | 2008-12-11 | 2016-08-10 | Respivert Limited | P38 map kinase inhibitors |
| JP2012513410A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| US8809343B2 (en) | 2008-12-26 | 2014-08-19 | Fudan University | Pyrimidine derivative, preparation method and use thereof |
| JP5766177B2 (ja) | 2009-03-27 | 2015-08-19 | ベトディーシー，インコーポレイテッド | ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921731D0 (en) * | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| CN102892752B (zh) | 2010-03-15 | 2015-03-25 | 宇部兴产株式会社 | 制备酰胺化合物的方法 |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| WO2011124923A2 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
| JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| GB201010193D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| PL2763984T3 (pl) | 2011-10-03 | 2016-10-31 | 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP | |
| EP2578582A1 (en) * | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| EP2981535B8 (en) | 2013-04-02 | 2021-03-10 | Oxular Acquisitions Limited | Urea derivatives useful as kinase inhibitors |
| WO2014162121A1 (en) | 2013-04-02 | 2014-10-09 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| US10284974B2 (en) | 2013-07-10 | 2019-05-07 | Starkey Laboratories, Inc. | Acoustically transparent barrier layer to seal audio transducers |
| JP6586098B2 (ja) | 2014-02-14 | 2019-10-02 | レスピバート・リミテツド | キナーゼ阻害剤としてのピラゾリル尿素 |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
-
2011
- 2011-10-03 EP EP11183688.8A patent/EP2578582A1/en not_active Ceased
-
2012
- 2012-10-03 EP EP12772382.3A patent/EP2763983B1/en active Active
- 2012-10-03 US US14/349,356 patent/US9475796B2/en active Active
- 2012-10-03 WO PCT/GB2012/052444 patent/WO2013050756A1/en not_active Ceased
- 2012-10-03 JP JP2014532481A patent/JP6023204B2/ja active Active
-
2016
- 2016-09-08 US US15/259,505 patent/US9724347B2/en active Active
-
2017
- 2017-06-29 US US15/636,730 patent/US9993478B2/en active Active
-
2018
- 2018-03-19 US US15/925,384 patent/US10238658B2/en active Active
-
2019
- 2019-02-26 US US16/285,560 patent/US10813932B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528403A5 (OSRAM) | ||
| JP2010526814A5 (OSRAM) | ||
| US8703788B2 (en) | Polymorph of nilotinib hydrochloride | |
| JP2018535967A5 (OSRAM) | ||
| JP2012530705A5 (OSRAM) | ||
| JP2012504590A5 (OSRAM) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JP2011527666A5 (OSRAM) | ||
| NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
| Amin et al. | Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity | |
| JP2013537203A5 (OSRAM) | ||
| JP2012507535A5 (OSRAM) | ||
| JP2011519854A5 (OSRAM) | ||
| JP2014516360A5 (OSRAM) | ||
| JPWO2011065541A1 (ja) | 抗腫瘍効果増強剤 | |
| JP2017526711A5 (OSRAM) | ||
| NZ598294A (en) | Heterocyclic compounds for the inhibition of pask | |
| JP6463680B2 (ja) | 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類 | |
| JP2008528542A5 (OSRAM) | ||
| JP6413032B2 (ja) | 新規ｄｇａｔ２阻害剤 | |
| JP2013534245A5 (OSRAM) | ||
| JPWO2008111604A1 (ja) | 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| JP2012509265A5 (OSRAM) | ||
| RU2017112299A (ru) | Способ получения ароматического гетероциклического соединения, применяемого в качестве селективного ингибитора киназы jak1, и применение ароматического гетероциклического соединения | |
| JP2010537994A5 (OSRAM) |